Application Submission Restrictions
-
Applicants may only submit one LOI per cycle and one invited full proposal per cycle, but a single academic institution may have multiple applicants apply for funding for different projects within a cycle. Biotechnology companies are limited to the submission of one LOI and one invited full proposal per cycle.
-
For Therapeutics RFPs, applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.
Application Review Process
-
Invited full proposals may be reviewed externally by members of our Scientific Review Board, which includes scientists from academia and industry with drug development expertise. Biotechnology proposals are also reviewed by members of our Business Review Board.
-
All active Scientific and Business Review Board members sign annual confidential disclosure agreements and must recuse themselves from reviewing any proposals with which they have a conflict of interest.
-
All ADDF Governors, officers, and advisory committee members who participate in the selection of recipients for research funding are required to annually complete conflict of interest questionnaires to avoid conflicts of interest and maintain high ethical standards.
-
For Therapeutics RFPs, applicants unable to submit the full proposal by the deadline may submit their proposal during the next cycle without submitting a new LOI, unless the proposed work has changed. After two missed deadlines, applicants must submit a new LOI.
Follow-On Funding
ADDF-funded investigators that wish to apply for follow-on funding are encouraged to contact ADDF scientific staff three months prior to the end of the funding period. The ADDF staff will schedule a conference call to discuss progress made towards the milestones and future plans for the program. Investigators will then be invited to submit a full proposal for follow-on funding through the standard application procedures.
Funding Mechanism
ADDF follows a venture philanthropy model. Funding is provided to academic/nonprofit and biotechnology/for-profit entities through the funding mechanism of mission related investments (MRI), which support the mission of the ADDF. This funding mechanism is structured to enable the ADDF to receive a return on investment, which is returned to the ADDF to increase its capacity to support more research in furtherance of its charitable mission. Terms of agreements may vary. Please contact grants@alzdiscovery.org with questions regarding this policy or the application process.
Allowable and Unallowable Costs
-
The ADDF's mission is to accelerate discovery of a novel treatment for Alzheimer's disease and other related dementias. The ADDF seeks to fulfill its mission by providing funding for development projects. As a public charity, the ADDF’s funding must be used specifically for an approved scientific project that advances the ADDF's stated mission.
-
ADDF funding may be provided for approved personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials.
-
ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).